Symbols

Enlivex Therapeutics Soars 14.61% on Clinical Trial Data

Generated by AI AgentAinvest Pre-Market Radar

Friday, Aug 15, 2025 6:52 am ET1min read

Aime Summary

- Enlivex Therapeutics' stock surged 14.61% pre-market on Aug 15, 2025, driven by Phase IIa trial updates and upcoming data presentations.

- The company will present 3-month topline data from its knee osteoarthritis trial on Aug 18, 2025, expected to impact investor sentiment.

- A concurrent webinar at 8:00 AM ET will share results, drawing attention from investors and analysts ahead of key market decisions.

Enlivex Therapeutics' stock surged 14.61% in pre-market trading on August 15, 2025, driven by significant developments in its clinical trials and upcoming data presentations.

The company is set to present 3-month topline data from its Phase IIa trial of ENX-CL-05-001, a multi-center, two-stage Phase I/II trial. This presentation is scheduled for August 18, 2025, and will provide a detailed analysis of the trial's progress and results, which is expected to influence investor sentiment and stock performance.

Enlivex Therapeutics has also announced a webinar to share the 3-month topline results from its Phase IIa trial for knee osteoarthritis. This event is scheduled for August 18, 2025, at 8:00 AM ET, and is anticipated to attract significant attention from investors and analysts.

Ainvest Pre-Market Radar

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue